Treatment of @entity3052 in XXXX .

@entity632 @entity1 @entity981 @entity59275 @entity332 @entity3052 @entity2592 @entity16897
Progress in the treatment of childhood @entity3052 has not equalled the advances obtained in the management of @entity981 . Two recent chemotherapy studies (i.e. @entity16897 and @entity59275 ), however, reported marked increase in the proportion of long-term remissions. The initial therapy of the cooperative study @entity59275 consisted of two 4-week phases of intensive induction/consolidation with 7 different drugs and cranial irradiation followed by maintenance with @entity332 and @entity2592 for 2 years and additional @entity632 during the first year. A total of 151 @entity1 with @entity3052 were enrolled in the study from 30 centers. Of these 119 (79%) @entity1 achieved complete remission. After a median observation time of 34 (14-57) months, there have been 46 relapses. CNS was involved in 6 of these relapses. Life table analyses revealed the following probabilities after 4 1/2 years: survival: 46%; disease-free survival: 41% (total group), 52% (remission group); disease-free interval 56% (remission group). The risk of relapse appears to decrease considerably after 2 1/2 years. No risk factors for the occurrence of relapse have been identified.
